tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Arcus Biosciences reports Q3 EPS ($1.27), consensus ($1.29)
PremiumThe FlyArcus Biosciences reports Q3 EPS ($1.27), consensus ($1.29)
2d ago
Arcus Biosciences Advances Cancer Treatment with AB801 Study
Premium
Company Announcements
Arcus Biosciences Advances Cancer Treatment with AB801 Study
3d ago
Arcus Biosciences Advances Phase 3 Trial for Renal Cell Carcinoma
Premium
Company Announcements
Arcus Biosciences Advances Phase 3 Trial for Renal Cell Carcinoma
3d ago
Positive Outlook for Arcus Biosciences Driven by Promising Phase 2 Trial Results and Broader Patient Applicability
PremiumRatingsPositive Outlook for Arcus Biosciences Driven by Promising Phase 2 Trial Results and Broader Patient Applicability
17d ago
Arcus announces first OS results from Arm A1 of Phase 2 EDGE-Gastric study
Premium
The Fly
Arcus announces first OS results from Arm A1 of Phase 2 EDGE-Gastric study
18d ago
Arcus Biosciences price target raised to $39 from $32 at Truist
Premium
The Fly
Arcus Biosciences price target raised to $39 from $32 at Truist
23d ago
Arcus Biosciences announces new data for casdatifan
PremiumThe FlyArcus Biosciences announces new data for casdatifan
24d ago
Gilead and Arcus Biosciences’ Promising Phase 3 Lung Cancer Study: Market Implications
Premium
Company Announcements
Gilead and Arcus Biosciences’ Promising Phase 3 Lung Cancer Study: Market Implications
2M ago
Gilead and Arcus Advance Promising Colorectal Cancer Study
Premium
Company Announcements
Gilead and Arcus Advance Promising Colorectal Cancer Study
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100